跳至主要内容
临床试验/EUCTR2007-000151-33-NL
EUCTR2007-000151-33-NL进行中(未招募)1 期

Does caffeine reduce rosuvastatin-induced protection against ischemia-reperfusion injury? - rosucof

MC0 个研究点目标入组 24 人开始时间: 2007年3月2日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
MC
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • -age between 18-50 yrs
  • -signed informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years)
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Cardiovascular disease
  • -Hypertension (systole > 140 mmHg, diastole > 90 mmHg)
  • -Hypercholesterolemia (fasting total cholesterol > 6,0 mmol/l)
  • -Drug abuse
  • -Concomittant medication use
  • -Inability to perform the ischemic isometric muscle contraction
  • -Diabetes Mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)
  • -Alanine-Amino-Transferase (ALAT) >90U/L (more than twice the upper level of the normal
  • -Creatinine Kinase (CK) >340U/L (more than twice the upper level of the normal range)
  • -Participation in any trial concerning medicinal products
  • during the last 60 days prior to this study.
  • -Participation in clinical trial involving administration of radioactivity more than 5mSv, during the 5 years prior to this study.

研究者

发起方
MC

相似试验

Does caffeine reduce rosuvastatin-induced protection... | 临床试验